Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5984320 | 0.84 | HDAC8 (0.38) | HSD17B10HDAC8SMN1; SMN2RORCSPHK1 | |
| SCHEMBL1781623 | 0.83 | HSD17B10 (0.37) | HSD17B10HDAC8SMN1; SMN2SPHK1NR1H2 | |
| SCHEMBL1781626 | 0.83 | HSD17B10 (0.37) | HSD17B10HDAC8SMN1; SMN2SPHK1NR1H2 | |
| SCHEMBL10138493 | 0.83 | HSD17B10 (0.37) | HSD17B10HDAC8SMN1; SMN2SPHK1NR1H2 | |
| SCHEMBL25930944 | 0.82 | HSD17B10 (0.39) | HSD17B10HDAC8SMN1; SMN2RORCSPHK1 | |
| SCHEMBL18591178 | 0.82 | HSD17B10 (0.39) | HSD17B10HDAC8SMN1; SMN2RORCSPHK1 | |
| SCHEMBL22123778 | 0.80 | HSD17B10 (0.39) | HSD17B10HDAC8SMN1; SMN2RORCSPHK1 | |
| SCHEMBL20584483 | 0.80 | HSD17B10 (0.39) | HSD17B10HDAC8SMN1; SMN2RORCSPHK1 | |
| SCHEMBL22123735 | 0.80 | HSD17B10 (0.39) | HSD17B10HDAC8SMN1; SMN2RORCSPHK1 | |
| SCHEMBL17181248 | 0.80 | HSD17B10 (0.39) | HSD17B10HDAC8SMN1; SMN2RORCSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | HSD17B10 1162/4885HDAC8 2217/4885SMN1; SMN2 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.